How I treat non-transfusion-dependent β-thalassemia

被引:12
|
作者
Saliba, Antoine N. [1 ]
Musallam, Khaled M. [2 ]
Taher, Ali T. [3 ,4 ]
机构
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Burjeel Med City, Thalassemia Ctr, Abu Dhabi, U Arab Emirates
[3] Amer Univ, Beirut Med Ctr, Dept Internal Med, Beirut, Lebanon
[4] Amer Univ, Beirut Med Ctr, Dept Internal Med, POB 11-0236, Beirut 11072020, Lebanon
关键词
PULMONARY ARTERIAL-HYPERTENSION; LIVER IRON CONCENTRATION; INEFFECTIVE ERYTHROPOIESIS; SERUM FERRITIN; RISK-FACTORS; INTERMEDIA; SPLENECTOMY; HYDROXYUREA; MANAGEMENT; OVERLOAD;
D O I
10.1182/blood.2023020683
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The intricate interplay of anemia and iron overload under the pathophysiological umbrella of ineffective erythropoiesis in non-transfusion-dependent beta-thalassemia (NTDT) results in a complex variety of clinical phenotypes that are challenging to diagnose and manage. In this article, we use a clinical framework rooted in pathophysiology to present 4 common scenarios of patients with NTDT. Starting from practical considerations in the diagnosis of NTDT, we delineate our strategy for the longitudinal care of patients who exhibit different constellations of symptoms and complications. We highlight the use of transfusion therapy and novel agents, such as luspatercept, in the patient with anemia-related complications. We also describe our approach to chelation therapy in the patient with iron overload. Although tackling every specific complication of NTDT is beyond the scope of this article, we touch on the management of the various morbidities and multisystem manifestations of the disease.
引用
收藏
页码:949 / 960
页数:12
相关论文
共 50 条
  • [21] Clinical and Molecular Characteristics of Non-Transfusion-Dependent Thalassemia in Kuwait
    Adekile, Adekunle D.
    Azab, Asma F.
    Al-Sharida, Sondus I.
    Al-Nafisi, Bahia A.
    Akbulut, Nagihan
    Marouf, Rajaa A.
    Mustafa, Nada Y.
    HEMOGLOBIN, 2015, 39 (05) : 320 - 326
  • [22] Magnitude of Bone Disease in Transfusion-Dependent and Non-Transfusion-Dependent β-Thalassemia Patients
    Shamoon, Rawand P.
    Yassin, Ahmed K.
    Omar, Negar
    Saeed, Muhammad D.
    Akram, Reving
    Othman, Naska N.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (03)
  • [23] Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia
    Taher, Ali T.
    Temraz, Sally
    Cappellini, M. Domenica
    EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (05) : 495 - 509
  • [24] Iron overload in non-transfusion-dependent thalassemia: a clinical perspective
    Musallam, Khaled M.
    Cappellini, Maria D.
    Wood, John C.
    Taher, Ali T.
    BLOOD REVIEWS, 2012, 26 : S16 - S19
  • [25] Disease severity scoring system for non-transfusion-dependent thalassemia
    Wiwanitkit, Somsri
    Wiwanitkit, Viroj
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2016, 30 : E11 - E11
  • [26] The risk of severe bacterial infection in non-transfusion-dependent thalassemia
    Aoki, Yoshihiro
    PEDIATRIC RESEARCH, 2022, 92 (02) : 360 - 361
  • [27] HYDROXYUREA FOR NON-TRANSFUSION-DEPENDENT β-THALASSEMIA: A META-ANALYSIS
    Algiraigri, Ali
    Wright, Nicola
    Kassam, Aliya
    PEDIATRIC BLOOD & CANCER, 2015, 62 : 56 - 56
  • [28] Recent advances in the molecular understanding of non-transfusion-dependent thalassemia
    Galanello, Renzo
    BLOOD REVIEWS, 2012, 26 : S7 - S11
  • [29] Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes
    Ricchi, Paolo
    Marsella, Maria
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 6475 - 6482
  • [30] Management of non-transfusion-dependent β-thalassemia (NTDT): The next 5 years
    Musallam, Khaled M.
    Rivella, Stefano
    Taher, Ali T.
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (03) : E57 - E59